MX2022003929A - Compuestos de benzoxazinona como inhibidores dobles de klk5/7. - Google Patents

Compuestos de benzoxazinona como inhibidores dobles de klk5/7.

Info

Publication number
MX2022003929A
MX2022003929A MX2022003929A MX2022003929A MX2022003929A MX 2022003929 A MX2022003929 A MX 2022003929A MX 2022003929 A MX2022003929 A MX 2022003929A MX 2022003929 A MX2022003929 A MX 2022003929A MX 2022003929 A MX2022003929 A MX 2022003929A
Authority
MX
Mexico
Prior art keywords
klk5
compounds
dual inhibitors
benzoxazinone compounds
benzoxazinone
Prior art date
Application number
MX2022003929A
Other languages
English (en)
Inventor
Robert Zamboni
Andreas Betz
Original Assignee
Molecular Skin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Skin Therapeutics Inc filed Critical Molecular Skin Therapeutics Inc
Publication of MX2022003929A publication Critical patent/MX2022003929A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona compuestos y composiciones farmacéuticas que incluyen los compuestos para el tratamiento de una enfermedad de la piel asociada con la actividad proteolítica de una o más proteasas KLK, en donde los compuestos son de acuerdo a la fórmula (I): (ver Fórmula) (I), donde R es como se describe en la presente.
MX2022003929A 2019-10-01 2020-09-30 Compuestos de benzoxazinona como inhibidores dobles de klk5/7. MX2022003929A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962909006P 2019-10-01 2019-10-01
PCT/US2020/053369 WO2021067335A1 (en) 2019-10-01 2020-09-30 Benzoxazinone compounds as klk5/7 dual inhibitors

Publications (1)

Publication Number Publication Date
MX2022003929A true MX2022003929A (es) 2022-06-14

Family

ID=75274622

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003929A MX2022003929A (es) 2019-10-01 2020-09-30 Compuestos de benzoxazinona como inhibidores dobles de klk5/7.

Country Status (12)

Country Link
US (2) US11643420B2 (es)
EP (1) EP4037687A4 (es)
JP (1) JP2022551583A (es)
KR (1) KR20220091488A (es)
CN (1) CN114615984A (es)
AU (1) AU2020359526A1 (es)
BR (1) BR112022005881A2 (es)
CA (1) CA3151626A1 (es)
IL (1) IL291398A (es)
MX (1) MX2022003929A (es)
TW (1) TW202126631A (es)
WO (1) WO2021067335A1 (es)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
CA1309556C (en) 1987-06-09 1992-10-27 Masayuki Kokubo 4h-3,1-benzoxazin-4-one compounds and pharmaceutical composition thereoffor the inhibition of serine proteases
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
CA2224381A1 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
WO1998027980A2 (en) 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
CA2319551A1 (en) 1998-03-31 1999-10-07 Warner-Lambert Company Benzoxazinones/benzothiazinones as serine protease inhibitors
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
KR101099409B1 (ko) 2003-06-06 2011-12-27 아렉시스 악티에볼라그 피부 상태 또는 암 치료를 위한 ｓｃｃｅ 저해제로서의융합된 헤테로사이클 화합물의 용도
ES2820868T3 (es) * 2014-01-23 2021-04-22 Sixera Pharma Ab Derivados de benzoxazinona para el tratamiento de enfermedades cutáneas

Also Published As

Publication number Publication date
CN114615984A (zh) 2022-06-10
WO2021067335A1 (en) 2021-04-08
BR112022005881A2 (pt) 2022-06-21
TW202126631A (zh) 2021-07-16
CA3151626A1 (en) 2021-04-08
AU2020359526A1 (en) 2022-04-21
US20240067658A1 (en) 2024-02-29
JP2022551583A (ja) 2022-12-12
EP4037687A4 (en) 2023-09-27
US20210101911A1 (en) 2021-04-08
IL291398A (en) 2022-05-01
US11643420B2 (en) 2023-05-09
EP4037687A1 (en) 2022-08-10
KR20220091488A (ko) 2022-06-30

Similar Documents

Publication Publication Date Title
MX2022015812A (es) Inhibidores de cisteina proteasas y sus metodos de uso.
DE60231407D1 (de) Hemmende antikörper der her3-aktivität
EP1841426A4 (en) TERTIARY CARBINAMINES INCLUDING SUBSTITUTED HETEROCYCLES AS BETA SECRETASE INHIBITORS AND FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP1673078A4 (en) BENZYL ETHER AND BENZYLAMINO BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
CU23366B7 (es) Oxazolidinonas substituidas para terapia de combinación
EP1689713A4 (en) BENZYLETHER AND BETA-SECRETASE BENZYLAMINO INHIBITORS FOR TREATING ALZHEIMER'S DISEASE
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
MX2022006700A (es) Compuestos poliheterociclicos como inhibidores de mettl3.
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
BRPI0512970A (pt) prodrogas de inibidores da hiv protease
ATE333451T1 (de) Verwendung von nitrilenverbindungen als arztneimittel
ATE547396T1 (de) Dicycloalkylcarbamoyl-harnstoffe als glucokinase- aktivatoren
EA201001586A1 (ru) Соединения и композиции в качестве ингибиторов itpkb
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
MX2021007948A (es) Inhibidores de proteina de activacion de fibroblastos.
MXPA05012675A (es) Compuestos de hidroxiamidina e hidroxiguanidina como inhibidores de urocinasa.
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
BR112022000505A8 (pt) Compostos de 3,4-(anel fundido em 5)-5-fenil-pirrolidin-2-ona n-substituídos como inibidores de enzima isoqc e/ou qc
MX2014014066A (es) Compuestos de cromano.
MX2021009142A (es) Inhibidores topicos de fosfoinositol 3-cinasas.
MX2007011739A (es) Compuestos que contienen sulfonilo como inhibidores de cisteina proteasa.
MX2020004588A (es) Inhibidor de proteasa de doble cabeza.
MX2022003929A (es) Compuestos de benzoxazinona como inhibidores dobles de klk5/7.
ATE432936T1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
PH12017501668A1 (en) Bace1 inhibitors